- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00615108
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Changhua, Taiwan
- Boehringer Ingelheim Investigator Site
-
Chiayi, Taiwan
- Boehringer Ingelheim Investigator site 1
-
Chiayi, Taiwan
- Boehringer Ingelheim Investigator site 2
-
Keelung, Taiwan
- Boehringer Ingelheim Investigator Site
-
Ksohsiung, Taiwan
- Boehringer Ingelheim Investigator Site
-
Miaoli, Taiwan
- Boehringer Ingelheim Investigator Site
-
Taichung, Taiwan
- Boehringer Ingelheim Investigator site 1
-
Taichung, Taiwan
- Boehringer Ingelheim Investigator site 2
-
Tainan, Taiwan
- Boehringer Ingelheim Investigator site 1
-
Tainan, Taiwan
- Boehringer Ingelheim Investigator site 2
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 1
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 2
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 3
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 4
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 5
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 6
-
Taipei, Taiwan
- Boehringer Ingelheim Investigator site 7
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
1. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two criteria:
- Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) > 140 mmHg but < 180 mmHg, and/or diastolic BP > 90 mmHg but < 110 mmHg).
- Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.
Exclusion Criteria:
- Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
- Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
- Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Patients Achieving Blood Pressure (BP) Control
Tidsram: 01-Dec-2006 to 31-Dec-2008
|
BP control was defined as diastolic blood pressure/systolic blood pressure DBP/SBP< 90/140 mm-Hg during observation period.
BP is measured every four weeks.
The observation period is 8 weeks.
|
01-Dec-2006 to 31-Dec-2008
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Patients Achieving BP Response
Tidsram: 01-Dec-2006 to 31-Dec-2008
|
Achieving BP response was defined as reduction from baseline in sitting SBP or DBP > 10 mmHg during the observational period.
The observation period is 8 weeks.
|
01-Dec-2006 to 31-Dec-2008
|
Overall Assessment by Patients
Tidsram: 01-Dec-2006 to 31-Dec-2008
|
Overall assessment was reported as a 5-point scale rated from 0 to 4 as below: 4: Outstanding 3: Very satisfactory 2: Satisfactory 1: Marginal 0: Not satisfactory |
01-Dec-2006 to 31-Dec-2008
|
Overall Assessment by Attending Physicians
Tidsram: 01-Dec-2006 to 31-Dec-2008
|
Overall assessment was reported as a 5-point scale rated from 0 to 4 as below: 4: Outstanding 3: Very satisfactory 2: Satisfactory 1: Marginal 0: Not satisfactory |
01-Dec-2006 to 31-Dec-2008
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 502.519
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hypertoni
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Avslutad
-
NovartisAvslutad
-
NovartisAvslutadMETABOLISKT SYNDROM | HYPERTENSION | PRE-HYPERTENSIONFörenta staterna
-
Centre Chirurgical Marie LannelongueOkändKronisk trombo-embolisk pulmonell hypertension och pulmonell arteriell hypertensionFrankrike
-
NovartisAvslutadHYPERTENSION | HYPERKOLESTEROLEMIFörenta staterna
-
University Hospital, BonnRekryteringKardiomyopatier | Hypertoni, PortalTyskland
-
University Hospital, ToursAvslutadCirrhotic Portal HypertensionFrankrike
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeIntrahepatisk icke-cirrhotisk portalhypertoniFrankrike
-
Ain Shams UniversityAvslutad